Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week open-label randomized study of URIS I transcutaneous neuromodulation vs solifenacin in treatment-naive women with overactive bladder
2019-003321-14Phase 4Completed
- Sponsor
- Tesla Medical
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of solifenacin in overactive bladder (OAB) (2 arms), sponsored by Tesla Medical. Started Sep 2019; status: completed.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2019-003321-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003321-14.